Brain Corp’s Robotic Fleet Reaches Milestone of 100 Billion Square Feet Covered Autonomously
9.11.2021 15:00:00 EET | Business Wire | Press release
Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, today announced that its BrainOS®-powered fleet of autonomous mobile robots have officially reached 100 billion square feet of coverage. In doing so, 6.8 million hours have been given back to employees and operations managers, allowing them to focus on customer experience and other high-value tasks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005781/en/
Brain Corp’s Robotic Fleet Reaches Milestone of 100 Billion Square Feet Covered Autonomously (Graphic: Business Wire)
“We are thrilled to celebrate reaching 100 billion square feet of coverage with our fleet which represents the square footage of the entire commercial space in the United States,” said Eugene Izhikevich, CEO and Founder of Brain Corp. “The milestone represents a clear success of deploying autonomous robots at scale and across multiple industries. As a company committed to continuous improvement, it’s been incredibly gratifying to see such major advances in our fleet’s performance, even as it has been scaled and expanded to operate in multiple new dynamic public environments across the world.”
From October 1, 2020, to October 1, 2021, usage of automated robotics increased across a number of industry sectors with several seeing dramatic year-over-year growth. Increases in square feet covered autonomously within sectors include:
- Retail +40%
- Airports +69%
- Malls +113%
- Education +426%
- Hospitals +2,500%
While Brain Corp’s initial robot fleet growth was centered around retail environments, the significant increases in deployments within other sectors including malls, educational facilities, and hospitals, reflects the ability of BrainOS®-powered robots to learn the key dynamics of new environments, a critical factor in the ongoing advancement of its technology.
Creating AI software to power autonomous robots operating in new, varying environments requires advanced software and sensors that ensure high levels of performance and safety, all while prioritizing security and data protection. BrainOS®-powered robots align with all applicable privacy regulations, processing data exclusively for navigation and operational support without any additional data sources which could identify a natural person.
“As we’ve expanded our fleet size, our focus has always been on safely operating in a variety of different environments,” said Sean Felker, Lead Functional Safety Engineer. “Reaching 100 billion square feet of autonomous coverage is validation that this focus is paying off. We have always been committed to helping customers become more efficient in their operations, and it's a testament to our skilled teams that this is being successfully achieved while prioritizing safety and privacy.”
“This is an exceptionally exciting time to be in the field of robotics and automation,” said Nick Whitney, SVP, Sales America. “Across numerous industries, leaders are reinventing how they operate by combining the data-driven sophistication of automated robots with human teams.”
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data to enable the digital transformation of physical workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 16,000 AMRs, representing the largest fleet of its kind in the world. For more information, visit www.braincorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005781/en/
Contact information
Press
Josh Stanbury
press@braincorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom